Researchers from the Huntington's Disease Center, UCL Queen Square Institute of Neurology, and UK DRI at UCL have taken major ...

Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients with abnormal protein synthesis are treated to produce a healthy protein.

The Mt. Sinai study could open the door to future therapies for Alzheimer’s, amyotrophic lateral sclerosis, brain cancer, and ...

Scientists have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature ...

Scientists have developed a lipid nanoparticle system that enables mRNA to cross the blood-brain barrier, a long-standing challenge in n.

Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering ...

KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months ...

The Scientific Research and Experimental Development (SR&ED) tax incentives are intended to encourage businesses to conduct research and development in Canada. Corporations, individuals, trusts, and ...

Biomedical engineers have demonstrated a new synthetic approach that turbocharges bacteria into producing more of a specific ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

RBM42 reshaped the MYC mRNA blueprint to make it better for processing by ribosomes ... Disclosures: Ruggero is a shareholder of eFFECTOR Therapeutics, Inc. and is a member of its scientific advisory ...

RBM42 reshaped the MYC mRNA blueprint to make it better for processing ... Inc. and is a member of its scientific advisory board. The other authors declare no competing interests.